Soleno Therapeutics (NASDAQ:SLNO) Issues Earnings Results

Soleno Therapeutics (NASDAQ:SLNO) released its quarterly earnings results on Wednesday. The company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.64 by $0.16, FiscalAI reports. The firm had revenue of $91.73 million for the quarter, compared to analysts’ expectations of $88.55 million.

Here are the key takeaways from Soleno Therapeutics’ conference call:

• Strong financial launch: Q4 net revenue was $91.7M (FY2025 net revenue $190.4M on <9 months of sales), Soleno reached profitability (FY net income $20.9M), generated $48.7M cash from operations in Q4, and finished the year with ~$506M in cash and marketable securities, providing runway for commercialization and expansion.
• Commercial traction: Since launch there were 1,250 patient start forms (~12.5% of the U.S. addressable market), 859 active patients, 630 unique prescribers, and coverage for >180M lives, with the company targeting ~1,000 additional start forms over the next 9–12 months.
• Safety and retention: Real-world safety so far mirrors clinical expectations; launch-to-date discontinuation related to adverse events is ~12% (total discontinuation ~15%), and management expects a long-term discontinuation rate of 15–20%.
• EU regulatory progress: The MAA for DCCR (VYKAT XR) was validated, Day‑120 questions were answered, Day‑180 questions are expected imminently and a mid‑2026 EMA decision is anticipated; the company is preparing commercialization options for a meaningful EU market.
• Pipeline expansion plans: Soleno plans to file an IND for Glycogen Storage Disease Type I in H1 2026 and initiate a clinical program in late 2026, has orphan designations in US/EU, and is evaluating other rare-disease indications leveraging the same mechanism.

Soleno Therapeutics Stock Performance

SLNO traded up $0.75 during trading on Friday, reaching $38.84. 296,408 shares of the company’s stock were exchanged, compared to its average volume of 1,590,608. Soleno Therapeutics has a 1 year low of $32.63 and a 1 year high of $90.32. The company has a debt-to-equity ratio of 0.10, a current ratio of 16.08 and a quick ratio of 15.88. The stock has a market capitalization of $2.09 billion, a P/E ratio of 169.19 and a beta of -3.16. The company’s fifty day simple moving average is $42.80 and its 200-day simple moving average is $53.86.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Soleno Therapeutics by 1.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock valued at $1,242,000 after purchasing an additional 189 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Soleno Therapeutics by 50.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 633,110 shares of the company’s stock valued at $45,236,000 after buying an additional 213,667 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Soleno Therapeutics by 48.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 40,715 shares of the company’s stock worth $2,909,000 after buying an additional 13,211 shares during the last quarter. Creative Planning acquired a new stake in Soleno Therapeutics during the second quarter worth about $338,000. Finally, Prudential Financial Inc. purchased a new position in Soleno Therapeutics during the second quarter valued at approximately $413,000. Hedge funds and other institutional investors own 97.42% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on SLNO. Wall Street Zen raised shares of Soleno Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating and set a $120.00 target price (up from $110.00) on shares of Soleno Therapeutics in a research report on Tuesday, January 20th. Wolfe Research set a $60.00 price target on Soleno Therapeutics in a report on Monday, January 12th. Finally, Zacks Research lowered Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 3rd. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $108.38.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.